BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Beats Estimates By $0.15 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its earnings results on Wednesday. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15, FiscalAI reports. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 93.07% and a negative net margin of 40.90%.The firm’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.15 earnings per share.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%.
• The pediatric ORLADEYO pellets launch has begun strongly, with 47 prescriptions received by July 31—above the company’s full-year expectation—and early payer approvals and physician interest described as encouraging.
• BioCryst completed enrollment in the pivotal ALPHA-ORBIT trial of long-acting injectable navenibart ahead of schedule; top-line data are expected in the third quarter of 2027.
• The company raised 2026 total revenue guidance to $690 million-$715 million and lowered non-GAAP operating-cost guidance to $420 million-$440 million, supported by $113.2 million in second-quarter operating profit and more than $350 million in cash and investments.
• BioCryst is shutting down its Birmingham research unit and discontinuing internal discovery programs, shifting to externally sourced assets; management expects lower costs but must establish a stronger pipeline through future business-development transactions.

BioCryst Pharmaceuticals Trading Up 1.2%

Shares of BioCryst Pharmaceuticals stock traded up $0.11 on Friday, reaching $9.41. 1,344,062 shares of the company were exchanged, compared to its average volume of 4,978,475. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -6.27 and a beta of 0.55. The stock has a fifty day moving average price of $9.32 and a 200-day moving average price of $8.70.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. Focus Partners Wealth purchased a new stake in BioCryst Pharmaceuticals during the third quarter valued at about $77,000. Elevation Point Wealth Partners LLC purchased a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $81,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $81,000. Cetera Investment Advisers increased its position in shares of BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 1,494 shares in the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at approximately $103,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Needham & Company LLC lowered their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Royal Bank Of Canada decreased their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday. Citizens Jmp lifted their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Cantor Fitzgerald boosted their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.